Recombinant Avipox virus encoding polypeptide of mycoplasma gallisepticum, and utilized a live vaccine

• Main Authors: SAEKI; SAKIKO, TAKAHASHI; KIYOHITO, AOYAMA; SHIGEMI, IRITANI; YOSHIKAZU, OHKAWA; SETSUKO, OHSAWA; IKUROH, SAITOH; SHUJI, FUNATO; HIRONO
• Format: Patent
• Language: English
• Published: 16.02.1999
• Edition: 6
• Subjects: BEER; BIOCHEMISTRY; CHEMISTRY; COMPOSITIONS THEREOF; CULTURE MEDIA; ENZYMOLOGY; HUMAN NECESSITIES; HYGIENE; MEDICAL OR VETERINARY SCIENCE; METALLURGY; MICROBIOLOGY; MICROORGANISMS OR ENZYMES; MUTATION OR GENETIC ENGINEERING; ORGANIC CHEMISTRY; PEPTIDES; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES; PROPAGATING, PRESERVING OR MAINTAINING MICROORGANISMS; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS; SPIRITS; VINEGAR; WINE

PCT No. PCT/JP94/00541 Sec. 371 Date Sep. 25, 1995 Sec. 102(e) Date Sep. 25, 1995 PCT Filed Mar. 31, 1994 PCT Pub. No. WO94/23019 PCT Pub. Date Oct. 13, 1994A polypeptide exhibiting the antigenicity of Mycoplasma gallisepticum, a fused polypeptide comprising the above polypeptide and, connected to the N-terminus thereof, a signal membrane anchor of a type II outer-membrane polypeptide of a virus that infects birds, or a polypeptide capable of reacting with a mycoplasma-immune serum or a mycoplasma-infected serum and exhibiting a substantially pure antigenecity, respectively having amino acid sequences of about 32 kDa, about 40 kDa, or about 70 kDa. The expression with a recombinant virus of a polypeptide modified to such an extent as to exhibit an antigenicity equivalent to that of any of the above polypeptides. The use of a recombinant virus as a live vaccine.